Author(s)

Shigeru Kotake, Toru Yago, Manabu Kawamoto, Yuki Nanke

Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku, Japan.

In 2009, we demonstrated that a peptide, which we named “Peptide A”, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited both RANKL-induced human osteoclastogenesis and pit formation of mature human osteoclasts. Here, we examined the effect of Peptide A on the cell proliferation of cell lines of small-cell lung carcinoma, breast cancer, and prostate cancer: RERF-LC-MA, MCF-7, and PC-3, respectively. Peptide A inhibited the proliferation of RERF-LC-MA, but not MCF-7 or PC-3. TCTA protein was immunohistologically detected in RERF-LC-MA and MCF-7. Thus, Peptide A may provide a novel strategy for the therapy of the patients with small-cell lung carcinoma, especially with bone metastasis. In addition, Peptide A may be useful for the treatment of various cancer patients with bone metastasis.

Osteoclast; Small-Cell Lung Carcinoma; TCTA

Kotake, S. , Kawamoto, T. and Nanke, Y. (2013) A Novel Peptide from T-Cell Leukemia Translocation-Associated Gene (TCTA) Protein Inhibits Proliferation of a Small-Cell Lung Carcinoma. Journal of Cancer Therapy, 4, 44-46. doi: 10.4236/jct.2013.48A007.